1. Home
  2. PACK vs PRTA Comparison

PACK vs PRTA Comparison

Compare PACK & PRTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Ranpak Holdings Corp

PACK

Ranpak Holdings Corp

HOLD

Current Price

$3.59

Market Cap

485.2M

ML Signal

HOLD

Logo Prothena Corporation plc

PRTA

Prothena Corporation plc

HOLD

Current Price

$9.26

Market Cap

501.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
PACK
PRTA
Founded
1972
2012
Country
United States
Ireland
Employees
N/A
N/A
Industry
Containers/Packaging
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
485.2M
501.2M
IPO Year
2017
2013

Fundamental Metrics

Financial Performance
Metric
PACK
PRTA
Price
$3.59
$9.26
Analyst Decision
Buy
Buy
Analyst Count
3
9
Target Price
$6.50
$19.00
AVG Volume (30 Days)
634.3K
469.2K
Earning Date
06-10-2026
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$395,000,000.00
$814,000.00
Revenue This Year
$11.99
$1,111.38
Revenue Next Year
$8.16
N/A
P/E Ratio
N/A
N/A
Revenue Growth
7.08
N/A
52 Week Low
$2.91
$4.32
52 Week High
$6.31
$13.74

Technical Indicators

Market Signals
Indicator
PACK
PRTA
Relative Strength Index (RSI) 30.48 48.38
Support Level $3.34 $8.86
Resistance Level $3.79 $9.59
Average True Range (ATR) 0.31 0.48
MACD -0.15 -0.00
Stochastic Oscillator 15.67 41.50

Price Performance

Historical Comparison
PACK
PRTA

About PACK Ranpak Holdings Corp

Ranpak Holdings Corp is a provider of environmentally sustainable, systems-based, product protection solutions for e-Commerce and industrial supply chains. The company offers a full suite of protective packaging systems and paper consumables. Geographically, it derives a majority of its revenue from Europe/Asia. The group generates revenue by providing its PPS systems and paper consumables to customers, which include direct end-users and a network of exclusive paper packaging solution distributors, and by providing end-of-line automation systems that solve challenges, including optimization, customization, and efficiency. It has two segments, North America and Europe/Asia.

About PRTA Prothena Corporation plc

Prothena Corp PLC is a late-stage clinical biotechnology company that focuses on protein dysregulation and a pipeline of investigational therapeutics with the potential to change the course of devastating neurodegenerative and rare and peripheral amyloid diseases. Prothena is developing and applying its proprietary CYTOPE technology to target a broad spectrum of intracellular disease pathways in the brain and periphery. The company's pipeline includes both wholly-owned and partnered programs like Prasinezumab, Coramitug (PRX004), BMS-986446 (PRX005), PRX019, TDP-43 CYTOPE, and PRX012-TfR, being developed for the potential treatment of Parkinson's disease, ATTR amyloidosis with cardiomyopathy, Alzheimer's disease, Amyotrophic lateral sclerosis (ALS), and other neurodegenerative diseases.

Share on Social Networks: